He is Principal Investigator of an NIH-funded ancillary study that added longitudinal measurements of fibroblast growth factor-23 to the Chronic Renal Insufficiency Cohort (CRIC) Study. Dr. Wolf’s CRIC ancillary study is complementary to the CRIC ancillary study proposed as part of Aim 2 in the current application, and integration of the two ancillary studies will maximize knowledge derived from each. Dr. Wolf is also PI of a completed clinical trial of vitamin D2 (ergocalciferol) to which the current application proposes to add measurements of novel vitamin D metabolites. Dr. Wolf will devote 7.9% effort as Principal Investigator for the Northwestern University subcontract. For Aim 2 studies involving CRIC and his vitamin D2 clinical trial, Dr. Wolf will assist Dr. de Boer and Co-Investigators with study design, biosample selection, data analysis, and data interpretation, including appropriate data integration of data from his CRIC ancillary and vitamin D2 clinical trial. He will participate in the publication and presentation of results arising from these projects.
|Effective start/end date||4/15/14 → 7/31/16|
- University of Washington (UWSC7707//5R01DK099199-03)
- National Institute of Diabetes and Digestive and Kidney Diseases (UWSC7707//5R01DK099199-03)